Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 14/20 | 1.00 |
| ▸ | SLC5A2 | P31639 | 5/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phlorizin SCHEMBL16421567 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL113699 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL17290 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL18058585 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL22022720 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL23802544 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL28823647 | 0.99 | SLC5A1 (0.98) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL7647026 | 0.99 | SLC5A1 (0.98) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL18523288 | 0.99 | SLC5A1 (0.98) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 | |
| Phlorizin SCHEMBL8861774 | 0.99 | SLC5A1 (0.98) | SLC5A1SLC5A2SLC28A3HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20210330690-A1 | TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-2473606-B1 | Controlling transgene expression across the skin | ETH ZUERICH (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2473606-A1 | CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN | ETH Zurich (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2010115583-A1 | CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN | ETH ZURICH (CH) | 2010-10-14 | — | — | WO | disclosed |
| EP-2239326-A1 | Controlling transgene expression across the skin | ETH Zurich (CH) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330690-A1 | TREATING UNTREATED OR TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR | SLC5A2, SLC5A1, SLC2A1 | SLC5A1 2/4885SLC5A2 1/4885SLC28A3 107/4885 |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | SLC5A2, SLC5A1, SLC2A1 | SLC5A1 2/4885SLC5A2 1/4885SLC28A3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.